CTLA-4 antigen

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, Enriqueta Felip, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Kevin Jao, Fabrice Barlesi, Stéphanie Bordenave, Erika Rijavec, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Karim Vermaelen, Osvaldo Arén Frontera, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Helena Linardou, Elena Poddubskaya, David R Spigel, Samreen Ahmed, Michele Maio, Sunney Li, Han Chang, Joseph Fiore, Angelic Acevedo, Luis Paz-Ares

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006127; DOI: 10.1136/jitc-2022-006127
Targeting Cbl-b in cancer immunotherapy
Ryan C. Augustin, Riyue Bao, Jason J. Luke

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006007; DOI: 10.1136/jitc-2022-006007
Response to a letter to the editor: a better understanding of Immune Checkpoint Inhibitor-induced cholangitis for better management
Alexander Coukos, Julien Vionnet, Christine Sempoux, Montserrat Fraga

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006877; DOI: 10.1136/jitc-2023-006877
Acute kidney injury in patients treated with immune checkpoint inhibitors
Shruti Gupta, Samuel A P Short, Meghan E Sise, Jason M Prosek, Sethu M Madhavan, Maria Jose Soler, Marlies Ostermann, Sandra M Herrmann, Ala Abudayyeh, Shuchi Anand, Ilya Glezerman, Shveta S Motwani, Naoka Murakami, Rimda Wanchoo, David I Ortiz-Melo, Arash Rashidi, Ben Sprangers, Vikram Aggarwal, A Bilal Malik, Sebastian Loew, Christopher A Carlos, Wei-Ting Chang, Pazit Beckerman, Zain Mithani, Chintan V Shah, Amanda D Renaghan, Sophie De Seigneux, Luca Campedel, Abhijat Kitchlu, Daniel Sanghoon Shin, Sunil Rangarajan, Priya Deshpande, Gaia Coppock, Mark Eijgelsheim, Harish Seethapathy, Meghan D Lee, Ian A Strohbehn, Dwight H. Owen, Marium Husain, Clara Garcia-Carro, Sheila Bermejo, Nuttha Lumlertgul, Nina Seylanova, Lucy Flanders, Busra Isik, Omar Mamlouk, Jamie S Lin, Pablo Garcia, Aydin Kaghazchi, Yuriy Khanin, Sheru K Kansal, Els Wauters, Sunandana Chandra, Kai M Schmidt-Ott, Raymond K Hsu, Maria C Tio, Suraj Sarvode Mothi, Harkarandeep Singh, Deborah Schrag, Kenar D Jhaveri, Kerry L Reynolds, Frank B Cortazar, David E Leaf

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003467; DOI: 10.1136/jitc-2021-003467
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan D Curti, Walter J Urba, Brian D Piening, William L Redmond

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002663; DOI: 10.1136/jitc-2021-002663
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
Patrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, Evisa Gjini, Kristen D Felt, Jacquelyn O Wolff, Elizabeth I Buchbinder, Rizwan Haq, Ryan J Sullivan, Donald P Lawrence, David F McDermott, Mariano Severgnini, Anita Giobbie-Hurder, Scott J Rodig, F Stephen Hodi

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003318; DOI: 10.1136/jitc-2021-003318
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
Oliver Klein, Damien Kee, Bo Gao, Ben Markman, Jessica da Gama Duarte, Luke Quigley, Louise Jackett, Richelle Linklater, Andrew Strickland, Clare Scott, Linda Mileshkin, Jodie Palmer, Matteo Carlino, Andreas Behren, Jonathan Cebon

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003156; DOI: 10.1136/jitc-2021-003156
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, Ahmad A Tarhini, James Larkin, F Stephen Hodi, Jedd Wolchok, Michael A Postow, Brian Stwalley, Andriy Moshyk, Corey Ritchings, Sandra Re, Wim van Dijck, David F McDermott, Michael B Atkins

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003743; DOI: 10.1136/jitc-2021-003743
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Vikki Tang, Bryan Cho Wing Li, Roland Leung, Joanne Chiu, Ka Wing Ma, Wong Hoi She, Josephine Tsang, Chung Mau Lo, Tan To Cheung, Thomas Yau

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001945; DOI: 10.1136/jitc-2020-001945
Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors
Thomas Kelleher, Junliang Cai, Nicholas AJ Botwood, Dominic F Labriola

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001177; DOI: 10.1136/jitc-2020-001177

Main menu

CTLA-4 antigen

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

CTLA-4 antigen

Pages